PH10 (drug)
PH10 is a purported vomeropherine that is under development by VistaGen Therapeutics as a nasal spray for the treatment of major depressive disorder.[2][3][4][5]
| Clinical data | |
|---|---|
| Other names | PH10A; PH10 NS[1] |
| Routes of administration | Intranasal |
| Legal status | |
| Legal status |
|
References
- "PH-10 Nasal Spray". AdisInsight. Springer Nature Switzerland AG.
- "VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Retrieved 2019-12-19.
- "Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more". www.bizjournals.com. San Francisco Business Times. October 29, 2018. Retrieved 20 July 2020.
- Liebowitz MR, Nicolini H, Monti L, Hanover R (2013). "PH 10 may be a new rapidly acting intranasally administered antidepressant". American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, FL. Cite journal requires
|journal=(help) - Jancin B (2013). "Novel intranasal antidepressant shows results after 1 week". Clinical Psychiatry News. Retrieved 13 January 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.